L'esperienza con levofloxacina nelle polmoniti e nelle riacutizzazioni di bronchite cronica

Translated title of the contribution: Therapeutic experience with levofloxacin in pneumonia and COPD

Research output: Contribution to journalArticle

Abstract

The possible usefulness of levofloxacin in the empirical therapy of community acquired pneumonia, as monotherapy, (as alternative to the -lactam + macrolide combination) in once-a-day administration is supported by a body of evidence emerged from a wide world clinical documentation. Related to its possible use in sequential therapy, clinical and economic advantages are also been shown. In fact, a number of clinical experimental studies have evidenced that levofloxacin allows an earlier attainment of clinical stabilization, and resulting therapeutic switch, and is also associated with a more rapid and efficient achievement of outcomes, either early (microbiological response, time to clinical stabilization, length of stay) or late (clinical cure, radiological resolution, and mortality indexes), revealing a very favourable impact on cost-efficacy ratio. Published clinical studies concerning acute bacterial exacerbation of chronic bronchitis (ABECB) or chronic obstructive pulmonary (COPD) disease are also available, evidencing clinical and bacteriological efficacy of levofloxacin when compared to different therapeutic regimens, used at any severity grade, its use being related with a higher bacteriological eradication rate. However, caution must be observed in the use of fluoroquinolones for treatment of acute bacterial exacerbation of COPD, due to rising concern about possible bacterial resistance, especially in S. pneumonaie e P. aeruginosa, that might emerge towards this antimicrobial class, although, to date, levofloxacin appears to be only marginally affected, in terms of resistance rates and of clinical significance.

Original languageItalian
Pages (from-to)23-28
Number of pages6
JournalInfezioni in Medicina
Volume17
Issue numberSUPPL. 5
Publication statusPublished - 2009

Fingerprint

Levofloxacin
Chronic Obstructive Pulmonary Disease
Pneumonia
Therapeutics
Lactams
Chronic Bronchitis
Fluoroquinolones
Macrolides
Documentation
Reaction Time
Length of Stay
Economics
Costs and Cost Analysis
Mortality

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

L'esperienza con levofloxacina nelle polmoniti e nelle riacutizzazioni di bronchite cronica. / Blasi, Francesco.

In: Infezioni in Medicina, Vol. 17, No. SUPPL. 5, 2009, p. 23-28.

Research output: Contribution to journalArticle

@article{98b7dd4a377d4a358bfc6f20923600a9,
title = "L'esperienza con levofloxacina nelle polmoniti e nelle riacutizzazioni di bronchite cronica",
abstract = "The possible usefulness of levofloxacin in the empirical therapy of community acquired pneumonia, as monotherapy, (as alternative to the -lactam + macrolide combination) in once-a-day administration is supported by a body of evidence emerged from a wide world clinical documentation. Related to its possible use in sequential therapy, clinical and economic advantages are also been shown. In fact, a number of clinical experimental studies have evidenced that levofloxacin allows an earlier attainment of clinical stabilization, and resulting therapeutic switch, and is also associated with a more rapid and efficient achievement of outcomes, either early (microbiological response, time to clinical stabilization, length of stay) or late (clinical cure, radiological resolution, and mortality indexes), revealing a very favourable impact on cost-efficacy ratio. Published clinical studies concerning acute bacterial exacerbation of chronic bronchitis (ABECB) or chronic obstructive pulmonary (COPD) disease are also available, evidencing clinical and bacteriological efficacy of levofloxacin when compared to different therapeutic regimens, used at any severity grade, its use being related with a higher bacteriological eradication rate. However, caution must be observed in the use of fluoroquinolones for treatment of acute bacterial exacerbation of COPD, due to rising concern about possible bacterial resistance, especially in S. pneumonaie e P. aeruginosa, that might emerge towards this antimicrobial class, although, to date, levofloxacin appears to be only marginally affected, in terms of resistance rates and of clinical significance.",
keywords = "ABECB, COPD, Levofloxacin",
author = "Francesco Blasi",
year = "2009",
language = "Italian",
volume = "17",
pages = "23--28",
journal = "Infezioni in Medicina",
issn = "1124-9390",
publisher = "EDIMES Edizioni Medico Scientifiche",
number = "SUPPL. 5",

}

TY - JOUR

T1 - L'esperienza con levofloxacina nelle polmoniti e nelle riacutizzazioni di bronchite cronica

AU - Blasi, Francesco

PY - 2009

Y1 - 2009

N2 - The possible usefulness of levofloxacin in the empirical therapy of community acquired pneumonia, as monotherapy, (as alternative to the -lactam + macrolide combination) in once-a-day administration is supported by a body of evidence emerged from a wide world clinical documentation. Related to its possible use in sequential therapy, clinical and economic advantages are also been shown. In fact, a number of clinical experimental studies have evidenced that levofloxacin allows an earlier attainment of clinical stabilization, and resulting therapeutic switch, and is also associated with a more rapid and efficient achievement of outcomes, either early (microbiological response, time to clinical stabilization, length of stay) or late (clinical cure, radiological resolution, and mortality indexes), revealing a very favourable impact on cost-efficacy ratio. Published clinical studies concerning acute bacterial exacerbation of chronic bronchitis (ABECB) or chronic obstructive pulmonary (COPD) disease are also available, evidencing clinical and bacteriological efficacy of levofloxacin when compared to different therapeutic regimens, used at any severity grade, its use being related with a higher bacteriological eradication rate. However, caution must be observed in the use of fluoroquinolones for treatment of acute bacterial exacerbation of COPD, due to rising concern about possible bacterial resistance, especially in S. pneumonaie e P. aeruginosa, that might emerge towards this antimicrobial class, although, to date, levofloxacin appears to be only marginally affected, in terms of resistance rates and of clinical significance.

AB - The possible usefulness of levofloxacin in the empirical therapy of community acquired pneumonia, as monotherapy, (as alternative to the -lactam + macrolide combination) in once-a-day administration is supported by a body of evidence emerged from a wide world clinical documentation. Related to its possible use in sequential therapy, clinical and economic advantages are also been shown. In fact, a number of clinical experimental studies have evidenced that levofloxacin allows an earlier attainment of clinical stabilization, and resulting therapeutic switch, and is also associated with a more rapid and efficient achievement of outcomes, either early (microbiological response, time to clinical stabilization, length of stay) or late (clinical cure, radiological resolution, and mortality indexes), revealing a very favourable impact on cost-efficacy ratio. Published clinical studies concerning acute bacterial exacerbation of chronic bronchitis (ABECB) or chronic obstructive pulmonary (COPD) disease are also available, evidencing clinical and bacteriological efficacy of levofloxacin when compared to different therapeutic regimens, used at any severity grade, its use being related with a higher bacteriological eradication rate. However, caution must be observed in the use of fluoroquinolones for treatment of acute bacterial exacerbation of COPD, due to rising concern about possible bacterial resistance, especially in S. pneumonaie e P. aeruginosa, that might emerge towards this antimicrobial class, although, to date, levofloxacin appears to be only marginally affected, in terms of resistance rates and of clinical significance.

KW - ABECB

KW - COPD

KW - Levofloxacin

UR - http://www.scopus.com/inward/record.url?scp=77951608859&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77951608859&partnerID=8YFLogxK

M3 - Articolo

VL - 17

SP - 23

EP - 28

JO - Infezioni in Medicina

JF - Infezioni in Medicina

SN - 1124-9390

IS - SUPPL. 5

ER -